Sulfalene

Summary

Sulfalene (CHEMBL1525826) is an approved small molecule (ATC J01ED02); indicated across 2 conditions including bacterial infectious disease and malaria.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01ED02
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 280.31 Da · C11H12N4O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1525826
Name	Sulfalene
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9047
ATC	J01ED02
Molecular formula	C11H12N4O3S
Molecular weight	280.31
InChIKey	KXRZBTAEDBELFD-UHFFFAOYSA-N

SMILES: COC1=NC=CN=C1NS(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: 4-amino-N-(3-methoxypyrazin-2-yl)benzenesulfonamide

Also known as: AS-18908, Kelfizine w, Longum, NSC-110433, Sulfalene, Sulfaleno, Sulfamethopyrazine, Sulfamethoxypyrazine, Sulfametopyrazine, SID50086577, SID29216164, SULFALENE

Patent coverage: 13,134 distinct patent families (33,625 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Menin/Histone-lysine N-methyltransferase MLL.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
malaria	3	MONDO:0005136	EFO:0001068

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
Not specified	6
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01276626	PHASE1/PHASE2	COMPLETED	Study of Bacteria on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome
NCT06639516	Not specified	NOT_YET_RECRUITING	Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial
NCT07420231	Not specified	RECRUITING	Evaluation of the Synergistic Effect of Combining a Prebiotic and a Postbiotic on Intestinal Discomfort
NCT03056846	Not specified	COMPLETED	Probiotics on Stress-associated Gastrointestinal Function in University Students
NCT04042181	Not specified	UNKNOWN	The Effects of Supplementation of a Probiotic, B. Longum, on BMI and Anthropometric Outcomes in Overweight/Obese Adults.
NCT04911556	Not specified	UNKNOWN	the Effect of Probiotics on Aging Population
NCT05054309	Not specified	COMPLETED	A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).